September 5th 2025
In the midst of many changes surrounding aminoglycosides over the past several years, clinicians may be left wondering if these agents still have a role in modern clinical practice. This article summarizes changes impacting aminoglycosides, discusses where these agents may still have a role in the context of gram-negative infections, and explores future areas of study.
Top 5 Contagion® News Articles for the Week of June 18, 2017
June 24th 2017Pleuromutilin antibiotics, meningococcal disease, tuberculosis, a new fluoroquinolone to treat acute bacterial skin and skin structure infections, and WHO’s position on HPV vaccine recommendations makes up this week’s Top 5 articles.
Read More
Unnecessary Antibiotic Prescribing Can Result in Costly Adverse Effects
June 23rd 2017A new Johns Hopkins study finds that one fifth of hospitalized adults experience adverse effects from prescribed antibiotics; one fifth of those effects occurred in patients who should not have been prescribed antibiotics in the first place.
Read More
Market Pressures Hinder Access to Essential Antibiotics
June 20th 2017Commentary authors warn that lack of access to antibiotics to treat common bacterial infections are becoming difficult to access due to manufacturers finding them less profitable to produce and market; this can have serious implications.
Read More
Will Pennsylvania Proposal Sanction Improper Treatment of Lyme Disease?
June 16th 2017Amesh A. Adalja, MD, FIDSA argues that a bill being considered in the Pennsylvania state legislature will ultimately result in increased antibiotic resistance and will set back the clock for finding appropriate treatments for Lyme disease.
Read More
Why is Multidrug-Resistant Pseudomonas aeruginosa a Priority Pathogen?
June 13th 2017Jason Pogue, PharmD, BCPS-ID, Clinical Pharmacist, Infectious Diseases, Sinai-Grace Hospital, explains why Pseudomonas aeruginosa is one of the World Health Organization’s critical priority pathogens for new research and development priorities.
Watch